Health Condition 1: C189- Malignant neoplasm of colon, unspecified Health Condition 2: null- metastatic colorectal cancer
Conditions
Interventions
Intervention1: Panitumumab: Panitumumab is a fully human, IgG2 monoclonal antibody against epidernal growth factor recepto (EGFR). It is currently licensed in various regions across the world includin
Sponsors
Dr Reddys Laboratories Limited
Eligibility
Inclusion criteria
Inclusion criteria: Subject or subjectâ??s legally acceptable representative has provided informed consent Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum ï?· Metastatic disease Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status. ECOG performance status of 0, 1 or 2 (see Appendix 3) Measurable or non-measurable disease per RECIST Version 1.1. Must have failed after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens for metastatic disease Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen ï?· Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease Hematologic function, as follows: ï?· Absolute neutrophil count (ANC) >= 1.5 x 109/L ï?· Platelet count >= 75 x 109/L ï?· Hemoglobin >= 8.0 g/dL Renal function, as follows: ï?· Creatinine Hepatic function, as follows: ï?· Aspartate aminotransferase (AST) ï?· Alanine aminotransferase (ALT) ï?· Total Bilirubin Metabolic function, as follows: ï?· Serum Magnesium within normal limits ï?· Serum Calcium within normal limits ï?· Serum Potassium within normal limits All prior treatment related toxicities CTCAE version 4.03 Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception during the study and for 2 months following the last dose of study treatment.Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.
Exclusion criteria
Exclusion criteria: History or known presence of central nervous system metastases History of another malignancy except: ï?· Malignancy treated with curative intent and with no known active disease present for >= 5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician ï?· Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease ï?· Adequately treated cervical carcinoma in situ without evidence of disease ï?· Prostatic intraepithelial neoplasia without evidence of prostate cancer Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to panitumumab or excipients that contraindicates their participation. Prior anti-EGFr antibody therapy (e.g., panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib) Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy Other investigational procedure History of interstitial lung disease (ILD) e.g., interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest CT Subject previously enrolled to this study History of keratitis, ulcerative keratitis or severe dry eye Major surgery (e.g., requiring general anesthesia) Minor surgical procedure (e.g., open biopsy) = 3 days prior to first dose of study treatment is acceptable Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event Subject who is pregnant or breast feeding, or planning to become pregnant during treatment and within 2 months after the discontinuation of study treatment Known positive test(s) for human immunodeficiency virus infection (testing is not required in the absence of clinical suspicion) Active infection requiring systemic treatment or any uncontrolled infection Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to c
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of panitumumab in the labelled dose in 50 subjects with previously treated wild-type KRAS and wild-type NRAS metastatic colorectal cancerTimepoint: Laboratory evaluations every 4 weeks, Physical examination every 2 weeks, adverse event monitoring through out the study duration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS), Overall response rate (ORR) and Duration of responseTimepoint: Assessments every 8 weeks | — |
Countries
India
Contacts
Public ContactSachin S Joshi
Dr. Reddyâ??s Laboratories Ltd.
Outcome results
None listed